Evidence map›Paper›PMID 39400956›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2025

Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination.

Sho Fukui, Masato Okada, Tomohiro Shinozaki, Takahiro Suzuki, Takehiro Nakai, Hiroki Ozawa, Hiromichi Tamaki, Mitsumasa Kishimoto, Hiroshi Hasegawa, Takeaki Matsuda and 4 more

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sho FukuiBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, St. Luke's International Hospital, Tokyo, Japan, Kyorin University School of Medicine, Tokyo, Japan.ORCID 0000-0002-3082-1374
Masato OkadaSt. Luke's International Hospital, Tokyo, Japan.
Tomohiro ShinozakiTokyo University of Science, Tokyo, Japan.ORCID 0000-0003-3395-9691
Takahiro SuzukiSt. Luke's International Hospital, Tokyo, Japan.
Takehiro NakaiSt. Luke's International Hospital, Tokyo, Japan.ORCID 0000-0003-0588-9518
Hiroki OzawaSt. Luke's International Hospital, Tokyo, Japan.ORCID 0009-0002-4249-2376
Hiromichi TamakiSt. Luke's International Hospital, Tokyo, Japan.
Mitsumasa KishimotoSt. Luke's International Hospital and Kyorin University School of Medicine, Tokyo, Japan.ORCID 0000-0002-4007-1589
Hiroshi HasegawaKyorin University School of Medicine, Tokyo, Japan.
Takeaki MatsudaKyorin University School of Medicine, Tokyo, Japan.
Javier MarrugoBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-9157-4269
Sara K TedeschiBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-9475-1363
Hyon K ChoiMassachusetts General Hospital and Harvard Medical School, Boston.
Daniel H SolomonBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-8202-5428

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
NIAMS NIH HHS P30072577NIAMS NIH HHS P30 AR072577
6 · The paper itself

Abstract

objectiveOur objective was to evaluate associations of weight reduction with serum urate (SU) changes and achieving an SU level <6 mg/dL in the real-world setting, outside of specific weight reduction interventions.

methodsWe analyzed systematically collected data of annual medical examination participants from October 2012 to October 2022. Exposure was weight change (increase or decrease) between two consecutive visits, categorized as minimal (≤0.9 kg, reference), small (1.0-4.9 kg), moderate (5.0-9.9 kg), and large (≥10 kg). Outcomes included SU changes between two consecutive visits and achieving an SU level <6 mg/dL in participants with hyperuricemia (SU level ≥7 mg/dL at the previous visit).

resultsWe identified 58,630 eligible participants (median age 46 years, 51.3% female, 19.4% with overweight, median SU level 5.3 mg/dL, and 5.6% with a history of gout and/or hyperuricemia) with 336,814 visits over a median of 5.3 years. After adjustment for relevant covariates, linear general estimating equations estimated mean SU changes based on observed weight reductions (vs minimal changes) were as follows: small, -0.10 mg/dL (95% confidence interval [CI] -0.10 to -0.09 mg/dL); moderate, -0.34 mg/dL (95% CI -0.36 to -0.32 mg/dL); and large, -0.64 (95% CI -0.70 to -0.58 mg/dL). In participants with hyperuricemia, adjusted relative risks for achieving an SU level <6 mg/dL by modified Poisson regression were 1.25 (95% CI 1.15-1.37) in small weight reductions, 2.82 (95% CI 2.43-3.27) in moderate weight reductions, and 5.27 (95% CI 4.15-6.70) in large weight reductions, with corresponding numbers needed to treat of 61.1 for small weight reductions, 8.5 for moderate weight reductions, and 3.6 for large weight reductions.

conclusionSmall weight reductions were associated with only small SU changes. Some participants with hyperuricemia can achieve the target SU level with moderate to large weight reductions.

Indexed as

HyperuricemiaObesityOverweightUric AcidWeight LossAdultAgedFemaleGoutHumansLongitudinal StudiesMaleMiddle AgedUric Acid

Identifiers

PMID39400956
PMCPMC11867883

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.